Search Within

Claire Frances Friedman

Formats
  1. Meeting Abstract (59)
  2. Journal Article (53)
  3. Editorial (2)
  4. Book Section (1)
  5. Guidelines (1)
  6. Research Letter (1)
  7. Review (1)
Groups
  1. Department of Medicine (118)
  2. GDMT, Medicine (118)
  3. Gynecologic Medicine Service (118)
  4. Gynecology Disease Management Team (118)
  5. Solid Tumor Oncology Division (118)
  6. Weinberg Fellows (118)

More Groups

People
  1. Carol Aghajanian (43)
  2. Dmitriy Zamarin (40)
  3. Britta Weigelt (31)
  4. Roisin O'Cearbhaill (30)
  5. Nadeem Abu-Rustum (26)
  6. Vicky Makker (26)

More People

Years
  1. 2025 (6)
  2. 2024 (19)
  3. 2023 (11)
  4. 2022 (29)
  5. 2021 (12)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (25)
  2. Gynecologic Oncology (18)
  3. Annals of Oncology (11)
  4. International Journal of Gynecological Cancer (10)
  5. Journal for ImmunoTherapy of Cancer (10)
  6. Clinical Cancer Research (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (26)
  2. Elsevier Inc. (21)
  3. American Association for Cancer Research (14)
  4. Oxford University Press (14)
  5. Biomed Central Ltd (10)
  6. Lippincott Williams & Wilkins (10)

More Publishers

Results (118)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HLA class I subtypes are associated with immune-related adverse events in patients with melanoma treated with ipilimumab
    Meeting Abstract

    Safonov, A.; Pluta, J.; Qian, L.; Amaravadi, R.; Applegate, A.; Buchbinder, E.; Cohen, J.; Friedman, C.; Halaban, R.; Hodi, F. S.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • Clinical utility of prospective molecular characterization in advanced endometrial cancer
    Journal Article

    Soumerai, T. E.; Donoghue, M. T. A.; Bandlamudi, C.; Srinivasan, P.; Chang, M. T.; Zamarin, D.; Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Tew, W. P.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
    Journal Article

    Rosner, S.; Kwong, E.; Shoushtari, A. N.; Friedman, C. F.; Betof, A. S.; Brady, M. S.; Coit, D. G.; Callahan, M. K.; Wolchok, J. D.; Chapman, P. B.; more...
    Cancer Medicine (2018)

    Fulltext@MSK | Save
  • Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma
    Journal Article

    Shoushtari, A. N.; Friedman, C. F.; Navid-Azarbaijani, P.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Panageas, K. S.; Wolchok, J. D.; Chapman, P. B.
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Options for adjuvant therapy for uterine leiomyosarcoma
    Journal Article

    Friedman, C. F.; Hensley, M. L.
    Current Treatment Options in Oncology (2018)

    Fulltext@MSK | Save
  • Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors
    Meeting Abstract

    Friedman, C. F.; Wolchok, J. D.; Postow, M. A.; Shoushtari, A. N.; Callahan, M. K.; Momtaz, P.; Chapman, P. B.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Checkpoint inhibition and melanoma: Considerations in treating the older adult
    Journal Article

    Friedman, C. F.; Wolchok, J. D.
    Journal of Geriatric Oncology (2017)

    Fulltext@MSK | Save
  • Atypical autoimmune adverse effects with checkpoint blockade therapies
    Journal Article

    Friedman, C. F.; Snyder, A.
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Thinking critically about classifying adverse events: Incidence of pancreatitis in patients treated with nivolumab + ipilimumab
    Journal Article

    Friedman, C. F.; Clark, V.; Raikhel, A. V.; Barz, T.; Shoushtari, A. N.; Momtaz, P.; Callahan, M. K.; Wolchok, J. D.; Chapman, P. B.; Hellmann, M. D.; more...
    JNCI: Journal of the National Cancer Institute (2017)

    Fulltext@MSK | Save
  • Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP)
    Meeting Abstract

    Shoushtari, A. N.; Navid-Azarbaijani, P.; Friedman, C. F.; Panageas, K.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Campbell, S. C.; Shames, Y.; Prempeh-Keteku, N. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save